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Abstract
Background: Skin cancer is the most common cancer worldwide and commonly classified into malignant
melanoma (MM) and Nonmelanoma skin cancers (NMSCs), which mainly include basal cell carcinoma (BCC) and
squamous cell carcinoma (SCC). The extent to which Long Interspersed Element-1 (LINE-1, L1) ORF1p is expressed
in cutaneous malignancies remains to be evaluated. This study aimed to assess LINE-1 ORF1p immunoreactivity in
various skin cancer subtypes.
Method: The expression level of LINE-1 ORF1p was evaluated in 95 skin cancer specimens comprising 36 (37.9%)
BCC, 28 (29.5%) SCC, and 31 (32.6%) melanoma using the tissue microarray (TMA) technique. Then the association
between expression of LINE-1 encoded protein and clinicopathological parameters was analyzed.
Results: We showed that LINE-1 ORF1p expression level was substantially higher in BCC and SCC patients
compared with melanoma samples (p < 0.001). BCC cases had a higher LINE-1 histochemical score (H-score)
compared with SCC cases (p = 0.004). In SCC samples, a lower level of LINE-1 ORF1p expression was associated with
age younger than the mean (p = 0.041). At the same time, no significant correlation was found between LINE-1
ORF1p expression and other clinicopathological parameters (all p > 0.05).
Conclusions: According to our observation, LINE-1 ORF1p immunoreactivity in various skin tumor subtypes extends
previous studies of LINE-1 expression in different cancers. LINE-1ORF1p overexpression in NMSCs compared with
MM can be considered with caution as a tumor-specific antigen for NMSCs.
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Background
Cutaneous malignancy is one of the most common tu-
mors involving millions of humans around the world
and, unfortunately, on the rise. Skin cancers are gener-
ally classified as malignant melanoma (MM), which rep-
resents only 4% of skin cancer cases and non-melanoma
skin cancers (NMSC). NMSC includes two major sub-
types of BCC and SCC, amongst others [1, 2]. The inci-
dence rate of NMSC is 18–20 times higher than that
MM; however, it constitutes a relatively small percentage
of skin cancer deaths [3]. BCC and SCC are rarely fatal,
whereas 65–74% of deaths due to cutaneous cancer are
caused by malignant melanoma [4]. The high cure rate
is associated with BCC and SCC, especially when the le-
sion is small and diagnosed in early stages [1, 5]. The
early-stage melanoma may be hard to detect but is cur-
able, whereas metastatic form has a poor prognosis and
low survival rate [6].
Several risk factors including individual fair skin, blond
hair/red hair, freckling, age, gender, personal or family his-
tories, exposure to environmental UVR, high levels of ar-
senic in drinking water, polycyclic aromatic hydrocarbons,
smoking, genetic syndromes and taking immunosuppres-
sion are known to induce cutaneous malignancies [7, 8].
The development of skin cancer takes place in a multi-
step process by which the accumulation of mutations that
can result in genomic instability, which is a prominent fea-
ture of most cancers, such as melanoma [9]. One of the
mechanisms that are associated with genomic instability is
the activation of Transposable Elements (TEs).
TEs are categorized into two subgroups of DNA transpo-
sons and RNA transposons or retrotransposons [10]. Retro-
transposons can propagate themselves through the human
genome using RNA mediators. Long Interspersed Element-
1 (LINE-1, L1) accounts for about 17% of the human gen-
ome; however, their ability to construct eukaryotic genome
structure is a key factor throughout the evolution [11].
Most of these elements are 5′-truncated and incapable of
retrotransposition, but intact and full-length L1 elements
are still potent and active sequences in the human genome
[12]. A full-length L1 element is ∼6 kbp in length and di-
vided into three parts including 1) a 5′ untranslated region
(UTR) comprises an internal RNA polymerase II promoter;
2) two open reading frames (ORF1 and ORF2); 3) a 3′ UTR
which is finished with a variable polyA tail. ORF1 and
ORF2 are translated into an RNA-binding protein (40-kDa)
that has chaperone activity and a protein with endonuclease
and reverse-transcriptase activities (150- kDa), respectively
[10]. ORF1p trimers have a prominent role than ORF2p in
retrotransposition events such that ORF1p is generated
more than the ORF2p [13, 14]. The function of these el-
ements is intrinsically silenced in their promoters by
epigenetic modification and several trans-acting fac-
tors [14, 15].
In normal somatic cells, methylation is a powerful
mechanism of control over the activation of the retro-
transposable elements to avoid genomic instability,
chromosomal defects, and other genomic rearrange-
ments [16]. Global DNA hypomethylation is a critical
feature of human cancers; it may be due to the tran-
scriptional inactivation of LINE-1 elements [17]. LINE-1
promoter hypomethylation has been described in various
tumors, including lung cancer, colorectal cancers, breast
cancer, prostate cancer, liver cancer, ovarian cancer, and
esophageal cancer [14].
In non-small cell lung cancer (NSCLC), transcrip-
tional activation of L1 promoters by hypomethylation
results in genomic instability and unfavorable progno-
sis [18, 19], and in colorectal cancer emerges as an
early specific marker [20]. Both invasive and in situ
lesions of breast cancer have shown incomplete
methylation of LINE-1 promoter resulting in reduced
overall survival rate and treatment-resistant in youn-
ger patients [21, 22]. In a recent study, LINE-1 hypo-
methylation levels have been observed in melanoma
tumors thicker > 4 mm compared with normal mel-
anocyte primary cell cultures [23].
It has revealed that the production of ORF1p due to
the LINE-1 expression in in vitro transfected cells is
1000- to 10,000-fold higher levels compare to ORF2p
[24]. More than half of human cancers express LINE-1
ORF1p so that it could be considered as a highly speci-
fied tumor marker [17]. Up to now, there is no data re-
garding the expression of LINE-1 ORF1p in various skin
cancer subtypes. Based on previous studies [9, 25, 26], it
seems that MM may harbor a higher level of genomic
instability and heterogeneity compared with BCC and
SCC. This hypothesis raised the question as to whether
LINE-1 ORF1p expression differs among various skin
neoplasms, and if so, to what extent? In order to achieve
immunohistochemically expression data of LINE-1
ORF1p, we aimed to study the LINE-1 ORF1p expres-
sion levels by tissue microarray (TMA) in skin cancer
specimens comprising BCC, SCC, and melanoma.
Methods
Characteristics of patients and samples
A total of 139 formalin-fixed paraffin-embedded (FFPE)
specimens from various skin cancer patients were in-
cluded in the study. These archival tissue samples were
obtained from patients with primary skin cancer diag-
nosed in the Razi and Imam Khomeini Hospitals of
Tehran University of Medical Sciences, Tehran, Iran. Data
are presented for patients diagnosed with cancer between
2013 2016. Medical records were reviewed to obtain –
clinicopathological parameters comprising age, gender,
lesion type, tumor size, ulceration, metastasis, tumor-
infiltrating lymphocytes (TILs), perineural invasion (PNI),
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Clark and Breslow thickness scales (in melanoma), and
histological grade (in SCC). Not only the patient’s data
have no interference in their diagnosis and treatment, but
they also were completely kept anonymous. The Research
Ethics Committee of Tehran University of Medical Sci-
ences has approved all the study procedures (Ref no:
IR.TUMS.REC.1394.1733).
TMA construction
The entire skin cancer TMA blocks were created as de-
scribed previously [27–30]. Before TMA construction,
all hematoxylin and eosin-stained slides were reviewed
by our pathologist colleague (A-K). Then the most mor-
phologically representative areas of tumors in FFPE
blocks were annotated. To constructed TMA blocks, 0.6
mm diameter punches from the region of interests
(already annotated) transferred into one empty recipient
paraffin block. A TMA block was mad in triplicate 0.6-
mm cores of the marked area of each sample using
tissue-arraying equipment (MiniCore; ALPHELYS, Plai-
sir, France). Then 4 μm sections were cut from the com-
pleted recipient array blocks and transferred to adhesion
microscope slides. These glass slides were used for
immunohistochemically staining of LINE-1 ORF1p
antigenicity.
Immunohistochemistry
In brief, all the TMA slides were deparaffinized at 60 °C
for 20 min to be allowed for dehydration with two differ-
ent alcohol in grade. The solution of hydrogen peroxide
3% (v/v) for 20 min at room temperature was used for
blocking endogenous peroxidase. Following washing the
slides three times, the antigen retrieval step was per-
formed. This step was followed by autoclaving for 10
min at 121 °C using 10mM solution of sodium citrate
(pH 6.0). Then slides were incubated with the primary
monoclonal antibody (1:500 dilution), Anti-LINE 1
ORF1 (EMD Millipore, Cat. No MABC1152, CA, USA)
overnight at 4 °C. The slides were then incubated with a
secondary antibody cocktail of anti-rabbit/antimouse En-
vision (Dako, Denmark) for 30 min. Finally, substrate
and chromogen (3,3-diaminobenzidine DAB; Dako) was
added to the slides and followed by counterstaining with
hematoxylin visualize antigen (Dako, Denmark). After
dehydration in graded alcohols, slides were cleared in
xylene (Dako) and mounted for examination.
As mentioned, colorectal samples are positive for
LINE-1 ORF1p expression. We used them as a positive
control for confirming the immunolabeling of Anti-
LINE 1 ORF1. We also used normal skin samples as
negative control. Then we optimized and validated anti-
body titer and dilution on CRC samples as positive con-
trol and ten normal skin samples as a negative control.
To simultaneously compare the immunoreactivity of the
sample, all experiments were run with the same experi-
mental set-up.
Immunostaining assessment
Immunostaining of LINE-1 ORF1p was independently
reviewed by two well-experienced academic pathologists
(AK and AG) who were blinded to the patients’ outcome
and other clinical findings. A consensus outcome was
reached in case of discordance. A semi-quantitative scor-
ing approach was used to analyze the staining intensity
in slides [30]. First, slides were evaluated at 10× magnifi-
cation to find positive cores and overall distribution of
the tumor cells. Then the percentage of the stained area
was examined in high-power fields. The staining inten-
sity was scored as 0 (negative), 1 (weak), 2 (moderate),
and 3 (strong). The percentage of positive tumoral cells
was scored as < 25%, 25–50%, 50–75, and > 75% of
tumor cells. The histochemical score (H-score) was cal-
culated for each case by multiplying the staining inten-
sity and the percentage of positive tumor cells, which
yielded a range from 0 to 300. In this study, the mean
H-score was chosen to categorize samples as with high
or low LINE-1 ORF1p expression.
Statistical analysis
For comparison of LINE-1 staining scores in various
skin cancer subtypes, we did a two-sided Student’s t-test
to understand the difference between each group means.
Moreover, Pearson’s chi-square and Pearson’s R tests
were used to analyzing the significance of association
and correlation between LINE-1 ORF1p expression and
clinicopathological parameters. P values less than 0.05
were considered statistically significant.
Results
Following tissue processing and immunohistochemistry
staining of skin tumors, samples with missing one or two
cores were excluded from the study. A total of 95 samples
were included in this study. Of 95 cases, 28 (29.5%) were
SCC, 36 (37.9%) BCC, and 31 (32.6%) MM. The present
study comprises 67 and 28 male & female, respectively.
There was a male predominance in 3 groups and male to
female ratio in SCC, BCC, and MM were as follows: SCC
(23 males and five females: 4.6), BCC (26 males and ten fe-
males: 2.6) MM (18 males and 13 females: 1.38). The
mean age of patients in BCC, SCC, and MM subtypes of
skin cancers were calculated as 70.44 ± 10.2, 67.23 ± 12.6,
and 65.1 ± 14.2 years, respectively. Seven (19.4%), 2 (7.1%),
and 6 (19.4) patients of BCC, SCC and MM subtypes of
skin cancer had ulceration in pathological reports. In
terms of invasive and in situ forms in SCC, 2 (7.14) pa-
tients had in situ, whereas 12 (42.8%) had invasive form,
and for remaining of SCC patients, it was not available.
Margin involvement was seen in 1 (2.8%), 2 (7.1%), and 7
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(23.3%) patients of BCC, SCC, and MM patients. Tumor-
infiltrating lymphocytes as a prognostic factor and PNI
was found in 1 (3.6%) and 1 (3.6%) patients of SCC and 6
(19.4%) and 3 (9.7%) MM patients, respectively. Tumor
size was available for 8 (28.6%) SCC cases with a mean
value of 4-mm. Metastasis and local recurrence were avail-
able for 12 (38.7%) and 17 (54.8%) of MM patients,
respectively. Moreover 7 (22.6%) MM patients had lym-
phovascular invasion. Melanoma lesions are categorized
with Breslow thickness into ≤1 (thin melanoma) and > 1
mm (thick melanoma) [31]. Thin melanoma was found in
2 (6.5%) cases and thick melanoma in 8 (25.8%). In Clark’s
system, melanomas are divided into two groups: group 1
(Clark levels I and II) and group 2 (Clark levels III through
V). Seven (22.6%) melanoma cases were classified as group
2, and 6 (19.4%) as group 1 (Table 3), for the remaining it
was not available. Tables 1, 2 and 3summarize the clinico-
pathological features of skin cancer subtypes.
Analysis of LINE-1 ORF1p expression and its correlation
with clinicopathological features
We first tested LINE-1 ORF1p immunoreactivity on
normal skin tissue and colorectal tissues (Fig. 1). Follow-
ing optimization and validation of antibody titration and
dilution on CRC and normal skin tissues as a positive
and negative control, we did all controls and patients
tests simultaneously. Each tumor type was divided into
either lower (≤ mean of H-score) or higher (> mean of
H-score) LINE-1 ORF1p expression. The mean H-score
in BCC and SCC samples were 170.4 and 111.84,
respectively, whereas the mean H-score in melanoma
cases was 46.27. Twenty of 36 BCC samples (55.6%)
expressed lower levels of LINE-1 ORF1p, while 16
(44.4%) cases expressed higher levels (Fig. 2). Low ex-
pression of LINE-1 ORF1p was seen in 19 (67.9%) of 28
SCC cases, while high expression was found in 9 (32.1%)
samples (Fig. 2). Of the 31 melanoma samples, 22 (71%)
had a low expression, and 9 (29%) showed a high expres-
sion of LINE-1 ORF1p (Fig. 2). We found a highly sig-
nificant difference between mean H-score of LINE-1
ORF1p expression among the three tumor subtypes (all
p < 0.01). Box plot diagram of LINE-1 ORF1p expression
has been shown in (Fig. 3). Furthermore, the output of
the Mann-Whitney U test revealed a significant differ-
ence in LINE-1 ORF1p expression between BCC and
SCC (p = 0.004) and melanomas (p < 0.0001). Also, there
was a significant difference between the expression of
LINE-1 ORF1p in SCC and melanoma (p = 0.002).
Whereas, we could not find a significant correlation be-
tween studied clinicopathological parameters and LINE-
1 ORF1p expression in BCC and melanoma samples (all
p > 0.05) (Tables 1 & 3). A trend was evident between
LINE-1 ORF1p expression and ulceration (p = 0.07). In
SCC samples, a lower level of LINE-1 ORF1p expression
was associated with age lower than the mean (p = 0.041),
while no significant correlation was found between
LINE-1 ORF1p expression and other clinicopathological
parameters (all p > 0.05) (Table 2). Regarding the differ-
ent subtypes of lesions, we did not see any difference in
LINE-1 ORF1p immunolabeling of superficial versus




ORF1p expression (mean H-score = 170.4) P value
High (> 170.4) Low (< 170.4)
Mean age ± SD (70.44 ± 10.2 years) > 70 19 (52.8) 7 (36.8) 12 (63.2) 0.33
≤70 17 (47.2) 9 (52.9) 8 (47.1)
Gender Male 26 (72.2) 10 (38.5) 16 (61.5) 0.24
Female 10 (27.8) 6 (60) 4 (40)
Ulceration Yes 7 (19.4) 2 (28.6) 5 (71.4) 0.34
No 29 (80.6) 14 (48.3) 15 (51.7)
Histological subtypes Nodular 19 (52.8) 10 (52.6) 9 (47.4) 0.19
Pigmented 5 (13.9) 2 (40) 3 (60)
Infilterative 4 (11.1) 0 4 (100)
Adenoid 2 (5.6) 2 (100) 0
Micronodular 2 (5.6) 1 (50) 1 (50)
Metatypical 2 (5.6) 0 2 (100)
Sclerosing 1 (2.8) 0 1 (100)
Superficial 1 (2.8) 1 (100) 0
Margin involvement Yes 1 (2.8) 0 1 (100) 0.36
No 35 (97.2) 16 (45.7) 19 (54.3)
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nodular BCC, which are two main histological types of
BCC. Since the numbers are small and, therefore, would
not support a chi-squared test for trend on a contin-
gency with missing data. However, Fisher’s exact test
also was not significant for this analysis (P > 0.99). We
also could not find any positive trend between lentigo
and superficial spreading melanoma both in statistical
analysis, and pathological review. Also, it was the same
for BCC superficial versus nodular.
Discussion
In this study, we found LINE-1 ORF1p ORF1p immuno-
reactivity in various skin tumor subtypes that are in line
with previous studies of LINE-1 expression in different
cancers. As previously reported [32], ORF1p is expressed
200-fold than ORF2p, so tracking ORF1p throughout
disease progression can provide valuable insights regard-
ing retrotransposition events or the impact of LINE-1
expression on the genome.
Overall, LINE-1 ORF1p overexpression can be used as
a specific hallmark for diagnosing human malignancies
[17]. In the vast majority tumors including approxi-
mately 90% of breast, ovarian, pancreatic cancers, more
than half of tubular gastrointestinal tract cancers com-
prising esophageal and colon cancers and also 50% of
lung cancers and 40% of prostate tumors, ORF1p can be
detected by immunohistochemistry [14, 17]. As men-
tioned, LINE-1 activation/expression is associated with
genomic instability that is a hallmark and characteristics
in malignant tumors, including melanoma. Because of
this, we expected to get a wide range of LINE-1 expres-
sion in MM patients. In the current study, we found sig-
nificant expression of ORF1p in BCC samples in
comparison to SCC and melanoma. ORF1p immunola-
beling in BCC samples was higher than those of melan-
oma samples in contrary to our hypothesis. The reason
why the ORF1p expression in NMSC was higher than
malignant melanoma requires more attention.
Carcinogenesis in skin tissues is associated with ex-
posure to different environmental factors. Previous re-
ports have shown that some environmental factors
like gamma irradiation and X- rays some environmen-
tal agents such as benzo [a] pyrene (B [a]P), organo-
chlorine pesticides, food-borne carcinogens, extremely
low-frequency magnetic fields (ELF-MF) and some
heavy metals like arsenic, aluminum increase L1 ret-
rotransposition events [33–35]. Since the skin is the
first line of defense for mentioned factors, so the
higher expression of the level of ORF1 due to the ex-
posure to agents is plausible.




ORF1P expression (mean H-score = 111.84) P
valueHigh Low
Mean age + SD (67.23 ± 12.60 years) > 67 11 (39.3) 6 (54.5) 5 (45.5) 0.041
≤67 17 (60.7) 3 (17.6) 14 (82.4)
Gender Male 23 (82.1) 9 (39.1) 14 (60.9) 0.09
Female 5 (17.9) 0 5 (100)
Histological grade Well 13 (46.4 2 (15.4) 11 (84.6) 0.2
Moderate 11 (39.3) 5 (45.5) 6 (54.5)
Poor 4 (14.3) 2 (50) 2 (50)
Tumor size ≤4 mm 4 (14.3) 2 (50) 2 (50) 0.1
> 4mm 4 (14.3) 0 (0) 4 (100)
No data 20 (71.4) 7 (35) 13 (65)
Ulceration Yes 2 (7.1) 0 2 (100) 0.31
No 26 (92.8) 9 (34.6) 17 (65.5)
Tumor-infiltrating lymphocytes Yes 1 (3.6) 1 (100) 0 0.13
No 27 (96.4) 8 (29.6) 19 (70.4)
Perineural invasion (PNI) Yes 1 (3.6) 0 1 (100) 0.48
No 27 (96.4) 9 (33.3) 18 (66.7)
Invasive and in situ forms Invasive 12 (42.8) 7 (58.3) 5 (41.7) 0.25
In situ 2 (7.14) 2 (100) 0
No data 14 (50) 0 14 (100)
Margin involvement Yes 2 (7.1) 0 2 (100) 0.31
No 26 (92.8) 9 (34.6) 17 (65.4)
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Melanoma tumors have higher levels of genomic in-
stability [9] and are associated with hypomethylation of
genomic LINE-1 sequences [23, 36]. However, we ex-
pected to get more expression level of ORF1p in melan-
oma, what caused to observe such a decreased level in
comparison to other subtypes remains a mystery for us.
Likely, the monoclonal LINE-1 ORF1p antibody refer-
enced in this study that recognizes the sequence corre-
sponding to amino acids 35 to 44 of LINE-1 ORF1p
(MENDFDELRE) has not the capability for targeting
those sequences in melanoma. It seems that conven-
tional antigen retrieval pathways are not sufficient for re-
trieving LINE1 ORF1p immunolabelling. In SCC cases, a
trend towards increasing the correlation of ORF1p ex-
pression with age was observed, which supports the evi-
dence that age can play a role in developing SCC.
We observed both cytoplasmic and nuclear pattern of
LINE-1ORF1p expression in all of the samples, while the
cytoplasmic pattern has been predominantly represented
in some cancers [17]. In breast cancers, local relapse, as
well as distal metastases and poorer overall survival with
tumors displaying nuclear L1-ORF1p in contrast to cyto-
plasmic L1-ORF1p group, have been observed [37]. Dis-
tinguishing and quantification between cytoplasmic and
nuclear expression can be highlighted in skin tumor sub-
types in future studies.




ORF1P expression (mean H-score = 46.27) P
valueHigh Low
Mean age ± SD (65.1 ± 14.2 years) > 65 15 (48.4) 5 (33.3) 10 (66.7) 0.60
≤65 16 (51.6) 4 (25) 12 (75)
Gender Male 18 (58.1) 6 (33.3) 12 (66.7) 0.53
Female 13 (41.9) 3 (23.1) 10 (76.9)
Ulceration Yes 6 (19.4) 0 6 (100) 0.07
No 18 (58.1) 7 (38.9) 11 (61.1)
No data 7 (22.6) 2 (28.6) 5 (71.4)
Perineural invasion (PNI) Yes 3 (9.7) 0 3 (100) 0.21
No 20 (64.5) 7 (35) 13 (65)
No data 8 (25.8) 2 (25) 6 (75)
Metastasis Yes 12 (38.7) 6 (50) 6 (50) 0.26
No 8 (25.8) 2 (25) 6 (75)
No data 11 (35.5) 1 (9.1) 10 (90.9)
Local recurrence Yes 17 (54.8) 7 (41.2) 10 (58.8) 0.16
No 3 (9.7) 0 3 (100)
No data 11 (35.5) 2 (18.2) 9 (81.8)
Tumor-infiltrating lymphocytes Yes 6 (19.4) 0 6 (100) 0.19
No 4 (12.9) 1 (25) 3 (75)
No data 21 (67.7) 8 (38.1) 13 (61.9)
Lymphovascular invasion Yes 7 (22.6) 1 (14.3) 6 (85.7) 0.79
No 5 (16.1) 1 (20) 4 (80)
No data 19 (61.3) 7 (36.8) 12 (63.2)
Margin involvement Yes 7 (23.3) 2 (28.6) 5 (71.4) 0.5
No 18 (60) 3 (16.7) 15 (83.3)
No data 6 (16.7) 4 (66.7) 2 (33.3)
Breslow thickness Thin (≤1 mm) 2 (6.5) 0 2 (100) 0.59
Thick (> 1 mm) 8 (25.8) 1 (12.5) 7 (87.5)
No data 21 (67.7) 8 (38.1) 13 (61.9)
Clark level Group 1 (I, II) 7 (22.6) 1 (14.3) 6 (85.7) 0.33
Group 2 (III-V) 6 (19.4) 0 6 (100)
No data 18 (58.1) 8 (44.4) 10 (55.6)
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Fig. 1 IHC staining of colorectal, surgical intestinal resection margins in colon cancer, and normal skin tissues. a Positive immunoreactive LINE-1
ORF1p in CRC, b negative surgical resection margin sample for LINE-1 ORF1p, c and d are representative for normal skin tissues with
different magnifications
Fig. 2 Immunohistochemical analysis of LINE-1ORF1p expression in different skin cancer subtypes. LINE-1 ORF1p expression in SCC: a + 3, strong;
b + 2, moderate; c + 1, weak; d 0, no intensity. LINE-1ORF1p expression in BCC: e + 3, strong; f + 2, moderate; g + 1, weak; h 0, no intensity. LINE-
1ORF1p expression in melanoma: i + 3, strong; j + 2, moderate; k + 1, weak; l 0, no intensity
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Each genome harbors different copies of 80–100
potentially active L1 elements, and this partly explains
the variability in somatic insertions of L1 elements
within tumors [38]. How many full length - poten-
tially active elements contribute to immunoreactivity
for LINE-1 ORF1p and whether observed heterogen-
eity in these subsets of skin tumor subtypes is related
to differences in the inherited complement of active
L1 elements or not remains to be robustly evaluated.
Evaluating such heterogeneity in melanoma cases may
pave finding the reason for such differences. Since the
tumor microenvironment is a key contributor in cuta-
neous malignancies progression, studying L1 hypome-
thylation of functional L1 promoters and their
genomic sequences in precancerous lesions can offer
a genuine reservoir for finding novel targets for both
therapeutic purposes and risk assessments in skin
cancers.
In this context and according to our findings, clinical
information on the potential utility of LINE-1 ORF1p
expression and activation as a novel biomarker in skin
neoplasms are, however, limited, and future investiga-
tions should be directed towards identifying a correl-
ation between LINE-1 expression and histopathological
or diagnostic implication for practitioners is needed. If
the value of ORF1p expression is clinically validated in
SCC and BCC patients, such information will help clini-
cians make better decisions for prognosis and plan treat-
ment and follow-up of patients.
Conclusions
Evidence from basic and translational science indicates a
correlation between LINE-1 induction and tumorigen-
esis, cancer progression, and therapeutic response. Des-
pite ample evidence, the causal and mechanistic links
between LINE-1ORF1p expression and the development
Fig. 3 Box-plot diagram of LINE-1 ORF1p expression in skin tumor subtypes. In each panel, the vertical axis shows the total immunolabeling
score (H-score)
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of different cancers are still unraveled. According to our
observation, LINE-1 ORF1p immunoreactivity in various
skin tumor subtypes confirms previous studies of LINE-
1 expression in different cancers. LINE-1 ORF1p overex-
pression in NMSCs compared with MM can be consid-
ered with caution as a tumor-specific antigen for
NMSCs.
Abbreviations
NMSCs: Nonmelanoma skin cancers; LINE-1, L1: Long Interspersed Element-1;
ORF1p: Open reading frame 1 protein; MM: Malignant melanoma; BCC: Basal
cell carcinoma; SCC: Squamous cell carcinoma; TMA: Tissue microarray; H-
score: Histochemical score; UVR: Ultraviolet radiation; TEs: Transposable
Elements; UTR: Untranslated region; ORF: Open reading frame;
FFPE: Formalin-fixed paraffin-embedded; TILs: Tumor-infiltrating lymphocytes;
PNI: Perineural invasion; IHC: Immunohistochemistry
Acknowledgments
We are thankful to the staff of the Oncopathology Research Center, Iran
University of Medical Sciences, Tehran, Iran.
Authors’ contributions
All authors have read and approved the manuscript. MAZ, EK, ARK, ARG, AK
performed the research. AK and ZM designed the research study. ZM, NE,
AN-ER, KK contributed essential reagents or tools. AK analyzed the data. MAZ
and AK wrote the paper.
Funding
This research was supported by Deputy of Research and Technology, Tehran
University of Medical Sciences, Tehran, Iran, Grant/Award Number: 94–03-30-
29952. The funding source had no involvement in study design, collection,
analysis, and interpretation of data, writing of the report, and in the decision
to submit the article for publication.
Availability of data and materials
The data that support the findings of this study are available from the
corresponding author, [AK], upon reasonable request.
Ethics approval and consent to participate
The present study was performed in accordance with the 1975 Declaration
of Helsinki. Informed consent was obtained from all individual participants
included in the study. All experiments are approved by the Tehran University





The authors declare that there are no conflicts of interest to disclose
regarding funding from industrial sources or other disclosures concerning
this manuscript.
Author details
1Department of Molecular Medicine, Faculty of Advanced Medical Sciences,
Tabriz University of Medical Sciences, Tabriz, Iran. 2Department of
Dermatology, Razi Hospital, Tehran University of Medical Sciences, Tehran,
Iran. 3Oncopathology Research Center, Iran University of Medical Sciences,
Tehran, Iran. 4Department of Dermatopathology, Razi Dermatology Hospital,
Tehran University of Medical Sciences, Tehran, Iran. 5Autoimmune Bullous
Diseases Research Center, Tehran University of Medical Sciences, Tehran, Iran.
6Iran National Tumor Bank, Cancer Institute, Tehran University of Medical
Sciences, Tehran, Iran.
Received: 3 August 2019 Accepted: 8 June 2020
References
1. Gordon R. Skin cancer: an overview of epidemiology and risk factors. Semin
Oncol Nurs. 2013;29(3):160–9.
2. Fahradyan A, Howell AC, Wolfswinkel EM, Tsuha M, Sheth P, Wong AK.
Updates on the Management of Non-Melanoma Skin Cancer (NMSC).
Healthcare (Basel, Switzerland). 2017;5(4):82.
3. Apalla Z, Lallas A, Sotiriou E, Lazaridou E, Ioannides D. Epidemiological
trends in skin cancer. Dermatol Pract Concept. 2017;7(2):1–6.
4. Cummins DL, Cummins JM, Pantle H, Silverman MA, Leonard AL,
Chanmugam A. Cutaneous malignant melanoma. Mayo Clin Proc. 2006;
81(4):500–7.
5. Nerad JA. All skin cancers are not created equal. Br J Ophthalmol. 2007;
91(3):276–7.
6. Rigel DS, Russak J, Friedman R. The evolution of melanoma diagnosis: 25
years beyond the ABCDs. CA Cancer J Clin. 2010;60(5):301–16.
7. Netscher DT, Leong M, Orengo I, Yang D, Berg C, Krishnan B. Cutaneous
malignancies: melanoma and non-melanoma types. Plast Reconstr Surg.
2011;127(3):37e–56e.
8. Fabbrocini G, Triassi M, Mauriello MC, Torre G, Annunziata MC, De Vita V,
Pastore F, D'Arco V, Monfrecola G. Epidemiology of skin cancer: role of
some environmental factors. Cancers. 2010;2(4):1980–9.
9. Kaufmann WK, Carson CC, Omolo B, Filgo AJ, Sambade MJ, Simpson DA,
Shields JM, Ibrahim JG, Thomas NE. Mechanisms of chromosomal instability
in melanoma. Environ Mol Mutagen. 2014;55(6):457–71.
10. Cordaux R, Batzer MA. The impact of retrotransposons on human genome
evolution. Nat Rev Genet. 2009;10(10):691–703.
11. Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, Baldwin J, Devon K,
Dewar K, Doyle M, FitzHugh W, et al. Initial sequencing and analysis of the
human genome. Nature. 2001;409(6822):860–921.
12. Chen L, Dahlstrom JE, Chandra A, Board P, Rangasamy D. Prognostic value
of LINE-1 retrotransposon expression and its subcellular localization in
breast cancer. Breast Cancer Res Treat. 2012;136(1):129–42.
13. Sokolowski M, Chynces M, deHaro D, Christian CM, Belancio VP. Truncated
ORF1 proteins can suppress LINE-1 retrotransposition in trans. Nucleic Acids
Res. 2017;45(9):5294–308.
14. Ardeljan D, Taylor MS, Ting DT, Burns KH. The human long interspersed
Element-1 Retrotransposon: an emerging biomarker of Neoplasia. Clin
Chem. 2017;63(4):816–22.
15. Gong J, Zhang Q, Wang Q, Ma Y, Du J, Zhang Y, Zhao X. Identification and
verification of potential piRNAs from domesticated yak testis. Reproduction
(Cambridge, England). 2018;155(2):117–27.
16. Kerachian MA, Kerachian M. Long interspersed nucleotide element-1 (LINE-
1) methylation in colorectal cancer. Clin Chim Acta. 2019;488:209–14.
17. Rodic N, Sharma R, Sharma R, Zampella J, Dai L, Taylor MS, Hruban RH,
Iacobuzio-Donahue CA, Maitra A, Torbenson MS, et al. Long interspersed
element-1 protein expression is a hallmark of many human cancers. Am J
Pathol. 2014;184(5):1280–6.
18. Daskalos A, Nikolaidis G, Xinarianos G, Savvari P, Cassidy A, Zakopoulou R,
Kotsinas A, Gorgoulis V, Field JK, Liloglou T. Hypomethylation of
retrotransposable elements correlates with genomic instability in non-small
cell lung cancer. Int J Cancer. 2009;124(1):81–7.
19. Saito K, Kawakami K, Matsumoto I, Oda M, Watanabe G, Minamoto T. Long
interspersed nuclear element 1 hypomethylation is a marker of poor
prognosis in stage IA non-small cell lung cancer. Clin Cancer Res. 2010;16(8):
2418–26.
20. Sunami E, de Maat M, Vu A, Turner RR, Hoon DS. LINE-1 hypomethylation
during primary colon cancer progression. PLoS One. 2011;6(4):e18884.
21. van Hoesel AQ, van de Velde CJ, Kuppen PJ, Liefers GJ, Putter H, Sato Y,
Elashoff DA, Turner RR, Shamonki JM, de Kruijf EM, et al. Hypomethylation
of LINE-1 in primary tumor has poor prognosis in young breast cancer
patients: a retrospective cohort study. Breast Cancer Res Treat. 2012;134(3):
1103–14.
22. Park SY, Seo AN, Jung HY, Gwak JM, Jung N, Cho NY, Kang GH. Alu and
LINE-1 hypomethylation is associated with HER2 enriched subtype of breast
cancer. PLoS One. 2014;9(6):e100429.
23. Pramio DT, Pennacchi PC, Maria-Engler SS, Campos AH, Duprat JP, Carraro
DM, Krepischi AC. LINE-1 hypomethylation and mutational status in
cutaneous melanomas. J Investig Med. 2016;64(4):899–904.
Zolfaghari et al. BMC Cancer          (2020) 20:567 Page 9 of 10
24. Taylor MS, LaCava J, Mita P, Molloy KR, Huang CR, Li D, Adney EM, Jiang H, Burns
KH, Chait BT, et al. Affinity proteomics reveals human host factors implicated in
discrete stages of LINE-1 retrotransposition. Cell. 2013;155(5):1034–48.
25. Kabbarah O, Nogueira C, Feng B, Nazarian RM, Bosenberg M, Wu M, Scott KL,
Kwong LN, Xiao Y, Cordon-Cardo C, et al. Integrative genome comparison of
primary and metastatic melanomas. PLoS One. 2010;5(5):e10770.
26. Kabbarah O, Chin L. Revealing the genomic heterogeneity of melanoma.
Cancer Cell. 2005;8(6):439–41.
27. Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S,
Torhorst J, Mihatsch MJ, Sauter G, Kallioniemi OP. Tissue microarrays for
high-throughput molecular profiling of tumor specimens. Nat Med. 1998;
4(7):844–7.
28. Ronald Simon MM. And Guido Sauter: tissue microarrays. BioTechniques.
2004;36:98–105.
29. Sabet MN, Rakhshan A, Erfani E, Madjd Z. Co-expression of putative cancer
stem cell markers, CD133 and nestin, in skin tumors. Asian Pac J Cancer
Prev. 2014;15(19):8161–9.
30. Erfani E, Roudi R, Rakhshan A, Sabet MN, Shariftabrizi A, Madjd Z. Comparative
expression analysis of putative cancer stem cell markers CD44 and ALDH1A1 in
various skin cancer subtypes. Int J Biol Markers. 2016;31(1):e53–61.
31. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR,
Buzaid AC, Cochran AJ, Coit DG, Ding S, et al. Final version of 2009 AJCC
melanoma staging and classification. J Clin Oncol. 2009;27(36):6199–206.
32. Martin SL. Nucleic acid chaperone properties of ORF1p from the non-LTR
retrotransposon, LINE-1. RNA Biol. 2010;7(6):706–11.
33. Karimi A, Madjd Z, Habibi L, Akrami SM. Exposure of hepatocellular
carcinoma cells to low-level as (2) O (3) causes an extra toxicity pathway via
L1 retrotransposition induction. Toxicol Lett. 2014;229(1):111–7.
34. Karimi A, Madjd Z, Habibi L, Akrami SM. Evaluating the extent of LINE-1
mobility following exposure to heavy metals in HepG2 cells. Biol Trace Elem
Res. 2014;160(1):143–51.
35. Del Re B, Marcantonio P, Gavoci E, Bersani F, Giorgi G. Assessing LINE-1
retrotransposition activity in neuroblastoma cells exposed to extremely low-
frequency pulsed magnetic fields. Mutat Res. 2012;749(1–2):76–81.
36. Hoshimoto S, Kuo CT, Chong KK, Takeshima TL, Takei Y, Li MW, Huang SK,
Sim MS, Morton DL, Hoon DS. AIM1 and LINE-1 epigenetic aberrations in
tumor and serum relate to melanoma progression and disease outcome. J
Investig Dermatol. 2012;132(6):1689–97.
37. Harris CR, Normart R, Yang Q, Stevenson E, Haffty BG, Ganesan S, Cordon-
Cardo C, Levine AJ, Tang LH. Association of nuclear localization of a long
interspersed nuclear element-1 protein in breast tumors with poor
prognostic outcomes. Genes Cancer. 2010;1(2):115–24.
38. Doucet-O'Hare TT, Rodic N, Sharma R, Darbari I, Abril G, Choi JA, Young Ahn
J, Cheng Y, Anders RA, Burns KH, et al. LINE-1 expression and
retrotransposition in Barrett's esophagus and esophageal carcinoma. Proc
Natl Acad Sci U S A. 2015;112(35):E4894–900.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Zolfaghari et al. BMC Cancer          (2020) 20:567 Page 10 of 10
